Ferroptosis, a new form of cell death, and its relationships with tumourous diseases.
Yu H, Guo P, Xie X, Wang Y, Chen G. · 2017
Read Ferroptosis, a new form of cell death, and its relationships with tumourous diseases. by Yu H, Guo P, Xie X, Wang Y, Chen G. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5345622.txt.
Introduction
Haitao Yu, Pengyi Guo, Xiaozai Xie, Yi Wang, and Gang Chen reviewed a new form of cell death in the Journal of Cellular and Molecular Medicine in 2017. The death, named ferroptosis, needs iron and a build-up of fat peroxides in the cell. It looks unlike the known death paths: the cell shrinks and its powerhouses grow dense, with none of the marks of orderly suicide or burst.
Two drug groups can set it off: one blocks a cystine import path, the other blocks a guard enzyme called GPx4. Some cancer drugs in wide use also trigger it by chance. Two body paths, a fat-making chain and a sulfur path, help tune the death. The review sums up its discovery and controls, then maps its place in tumors. Liver, kidney, pancreas, and blood cancers all show ties, which hints at fresh drug angles.
Catalog record
| CREATOR | Yu H, Guo P, Xie X, Wang Y, Chen G. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Ferroptosis, a new form of cell death, and its relationships with tumourous diseases By Haitao Yu, Pengyi Guo, Xiaozai Xie, Yi Wang, Gang Chen Published in: Journal of Cellular and Molecular Medicine DOI: 10.1111/jcmm.13008 ABSTRACT Abstract Ferroptosis is a newly discovered type of cell death that differs from traditional apoptosis and necrosis and results from iron‐dependent lipid peroxide accumulation. Ferroptotic cell death is characterized by cytological changes, including cell volume shrinkage and increased mitochondrial membrane density. Ferroptosis can be induced by two classes of small‐molecule substances known as class 1 (system X c − inhibitors) and class 2 ferroptosis inducers [glutathione peroxidase 4 (GPx4) inhibitors]. In addition to these small‐molecule substances, a number of drugs (e.g. sorafenib, artemisinin and its derivatives) can induce ferroptosis. Various factors, such as the mevalonate (MVA) and sulphur‐transfer pathways, play pivotal roles in the regulation of ferroptosis. Ferroptosis plays an unneglectable role in regulating the growth and proliferation of some types of tumour cells, such as lymphocytoma, ductal cell cancer of the pancreas, renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Here, we will first introduce the discovery of and research pertaining to ferroptosis; then summarize the induction mechanisms and regulatory pathways of ferroptosis; and finally, further elucidate the roles of ferroptosis in human tumourous diseases. INTRODUCTION A new form of cell death, ferroptosis, was recently discovered. Ferroptosis results from iron‐dependent lipid peroxide accumulation and is characterized mainly by cell volume shrinkage and increased mitochondrial membrane density without typical apoptotic and necrotic manifestations 1. Ferroptotic cell death can be induced by two classes of small‐molecule substances. Class 1 ferroptosis inducers include erastin, sulfasalazine (SAS), DPI2 and buthionine sulfoximine, which can inhibit system XC − and reduce the intracellular glutathione content, causing an oxidation‐reduction imbalance in cells. Class 2 ferroptosis inducers include Ras selective lethal 3 compound (RSL3), DPI7, DPI10, DPI12, DPI13, etc., which can directly inhibit glutathione peroxidase 4 (GPx4) 2 and ultimately lead to an accumulation of lipid peroxides. In addition, ferroptosis can be induced by various drugs (e.g. sorafenib, artemisinin and its derivatives) 3, 4. The regulatory factors of ferroptosis primarily include the mevalonate (MVA) pathway, sulphur‐transfer pathways and the HSF1‐HSPB1 system 5. Ferroptosis may occur during a variety of physiological and pathological processes in humans and animals. Research has revealed the involvement of ferroptosis inhuman diseases. In particular, by regulating the growth and proliferation of tumour cells, ferroptosis plays an unneglectable role in the occurrence and progression of various tumourous diseases. To date, researchers have found that a number of tumour cell types, including lymphocytoma ductal cell cancer of the pancreas, renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC) cells, are susceptible to ferroptosis 2, 6, 7. The goal of this review is to provide a general overview of current knowledge regarding the mechanisms underlying ferroptosis in cells, its role in the growth and proliferation of tumour cells, its relationship with human tumourous diseases, and the application of pro‐ferroptotic approaches in tumour treatment. DEFINITION AND DISCOVERY OF FERROPTOSIS What is ferroptosis? Iron (Fe) is the fourth most common element in the Earth's crust, and it plays a pivotal role in human bodies 8. It is essential for cell survival because of its involvement in oxygen transportation, DNA biosynthesis and ATP synthesis as an auxiliary factor of various proteins in the tricarboxylic acid (TCA) cycle and the electron transport chain 9. In addition, iron has been found to be closely related to the occurrence and progression of tumours, and disorders of iron metabolism might facilitate tumour growth 9, 10. In addition, the presence of iron, particularly divalent iron, greatly accelerates lipid peroxidation of saturated fatty acids in humans 11. During iron‐involving oxidative phosphorylation in mitochondria, cells produce reactive oxygen species (ROS) along with the generation of ATP. ROS levels that exceed the cell's anti‐oxidation capacity can lead to an oxidative stress response, which directly and indirectly damages large molecular substances such as proteins, nucleic acids and lipids 12, leading to cell injury or death. This newly discovered form of cell death is called ferroptosis. Ferroptosis differs from apoptosis and necrosis in the traditional sense and results from the accumulation of iron‐dependent lipid peroxide 1. Discovery of ferroptosis In the history of ferroptosis, ferroptosis inducers were actually discovered before ferroptosis was named. In a 2003 study using a large‐scale screening experiment to explore the killing effect of various chemical compounds on tumour cells, Stockwell et al. identified a new chemical compound, erastin, that can cause RAS‐mutated tumour cells to die in a manner different from traditional apoptosis 13. In 2008, Stockwell et al. discovered two new compounds, RSL3 and RSL5, that have the same effect as erastin. They also determined that the resulting cell death can be inhibited by an iron chelator, desferrioxamine B‐methane sulphonate (DFOM) and an antioxidant, vitamin E 14, confirming that this form of cell death is related to intracellular iron and ROS. In 2012, Stockwell et al. used the term ‘ferroptosis’ to describe this type of cell death caused by the accumulation of iron‐dependent lipid peroxides 1. Later, other chemical compounds, including sorafenib 15, artemisinins 4, 6, and a newly discovered five‐membered ring cyclic peroxide 1, 2‐dioxolane (FINO2) 16, were confirmed to have the ability to induce ferroptosis. Furthermore, the mechanisms underlying the induction of the key molecules, system XC − and GPx4, in ferroptosis were partially revealed 2, 17. Recently, Xie et al. published a relatively detailed summary of ferroptosis inducers, inhibitors and regulatory molecules 18. However, a number of questions remain unaddressed, including the role of iron in ferroptosis, the molecular mechanisms underlying the induction of ferroptosis by ROS, and the roles of ferroptosis in human diseases. DIFFERENCES BETWEEN FERROPTOSIS AND APOPTOSIS/NECROSIS Cell death is the final stage of cells; it is caused by cytotoxicity from either exogenous or endogenous substances. There are various forms of cell death, which were originally defined and differentiated based on cellular morphology. In 1972, Kerr et al. defined a type of hepatatrophy‐associated ‘automatically programmed’ cell death as ‘apoptosis’ 30, which is characterized by typical morphological changes such as chromosome shrinkage, chromatin condensation and peripheralization, and round or oval cytoplasmic fragment formation 1, 30. Later, using an electron microscope, Schweichel and Merker observed the death of embryotic cells during their development in rats treated with/without lethal embryo toxicants and divided this programmed cell death (PCD) into three types 31. Clarke named type III PCD ‘necrosis’ 32, which is a passive form of cell death. As research has progressed, an increasing number of cell death types has been discovered, including pyroptosis, necroptosis, parthanatos, autophagy, oncosis and ferroptosis. Ferroptosis differs considerably from other cell death types, such as apoptosis, necrosis, and autophagy, in various aspects, including morphology, biochemistry and genetics 1, 14. Ferroptosis does not result in morphological changes similar to the chromatin condensation that occurs during apoptosis, the loss of plasma membrane integrity that occurs during necrosis, or the formation of double membrane‐layered autophagic vacuoles that occurs during autophagy; instead, it manifests primarily as mitochondrial shrinkage and increased mitochondrial membrane density 1 (Table 1). [Table: The main morphological features, regulators, inducers and inhibitors of ferroptosis, apoptosis, necroptosis and autophagy] Ferroptosis can be induced by various types of small molecules, such as erastin, SAS and